Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients

JACC: Cardiovascular Interventions

Volumn 7, Issue 4, 2014, Pages 426-434

  Rollini, Fabiana ^a   Franchi, Francesco ^a   Tello Montoliu, Antonio ^a   Patel, Ronakkumar ^a   Darlington, Andrew ^a   Ferreiro, José Luis ^a   Cho, Jung Rae ^a   Muñiz Lozano, Ana ^a   Desai, Bhaloo ^a   Zenni, Martin M ^a   Guzman, Luis A ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

cangrelor; platelet reactivity; prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HUMAN; IN VITRO STUDY; INCUBATION TIME; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; TIME; UNITED STATES;

ADENOSINE MONOPHOSPHATE; AGED; BLOOD PLATELETS; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLORIDA; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOPROTEINS; PHOSPHORYLATION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION; THIOPHENES; TIME FACTORS;

EID: 84898834209     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.11.019     Document Type: Article

References (40)

1. G.N. Levine, E.R. Bates, and J.C. Blankenship et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
2. J.L. Anderson, C.D. Adams, and E.M. Antman et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e179 e347
3. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
4. D. Alexopoulos, I. Xanthopoulou, and A. Perperis et al. Factors affecting residual platelet aggregation in prasugrel treated patients Curr Pharm Des 19 2013 5121 5126
5. L. Bonello, M. Pansieri, and J. Mancini et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
6. D. Alexopoulos, T.E. Plakomyti, and I. Xanthopoulou Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity Int J Cardiol 154 2012 333 334
7. J.L. Ferreiro, M. Ueno, and A. Tello-Montoliu et al. Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy J Am Coll Cardiol Intv 6 2013 182 184
8. J.L. Ferreiro, and D.J. Angiolillo New directions in antiplatelet therapy Circ Cardiovasc Interv 5 2012 433 445
9. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
10. G. Parodi, R. Valenti, and B. Bellandi et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
11. M. Laine, R. Toesca, and J. Berbis et al. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention Thromb Res 132 2013 e15 e18
12. A. Tello-Montoliu, S.D. Tomasello, and J.L. Ferreiro et al. Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study J Am Coll Cardiol 59 2012 1681 1687
13. D.L. Bhatt, G.W. Stone, K.W. Mahaffey CHAMPION PHOENIX Investigators Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
14. P.G. Steg, D.L. Bhatt, and C.W. Hamm et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data Lancet 382 2013 1981 1992
15. R.F. Storey, R.G. Wilcox, and S. Heptinstall Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease Platelets 13 2002 407 413
16. B. Aleil, C. Ravanat, J.P. Cazenave, G. Rochoux, A. Heitz, and C. Gachet Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases J Thromb Haemost 3 2005 85 92
17. J.L. Ferreiro, M. Ueno, and A. Tello-Montoliu et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation J Thromb Thrombolysis 35 2013 155 164
18. R.A. Harrington, G.W. Stone, and S. McNulty et al. Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
19. D.L. Bhatt, A.M. Lincoff, C.M. Gibson CHAMPION PLATFORM Investigators Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
20. L. Bonello, J. Mancini, and M. Pansieri et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel J Thromb Haemost 10 2012 1999 2005
21. S. Goto, N. Tamura, H. Ishida, and Z.M. Ruggeri Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5′-diphosphate receptor stimulation and cyclic calcium signaling J Am Coll Cardiol 47 2006 155 162
22. S. Goto, N. Tamura, K. Eto, Y. Ikeda, and S. Handa Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate Circulation 105 2002 2531 2536
23. U.S. Tantry, L. Bonello, and D. Aradi et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and; Bleeding J Am Coll Cardiol 62 2013 2261 2273
24. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
25. M. Cattaneo High on-treatment platelet reactivity-definition and measurement Thromb Haemost 109 2013 792 798
26. S. Goto, and A. Tomiya High on-treatment platelet reactivity (HPR): what does it mean, and does it matter? Thromb Haemost 109 2013 177 178
27. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
28. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
29. D. Alexopoulos, V. Gkizas, and S. Patsilinakos et al. Double vs standard loading dose of ticagrelor: Onset of antiplatelet action in patients with STEMI undergoing primary PCI J Am Coll Cardiol 62 2013 940 941
30. Gizas V, Alexopoulos D, Xanthopoulou I, et al. A pharmacodynamics study of high (100mg) loading dose of prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Paper presented at: ALPIC (Advanced Learning on Platelets & Thrombosis International Course); January 18 to 23, 2013; Mestovo, Greece.
31. A.A. Heestermans, J.W. van Werkum, and D. Taubert et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 2008 776 781
32. D. Penela, M. Magaldi, and J. Fontanals et al. Hypothermia in acute coronary syndrome: brain salvage versus stent thrombosis? J Am Coll Cardiol 61 2013 686 687
33. A. Straub, S. Krajewski, and J.D. Hohmann et al. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target Arterioscler Thromb Vasc Biol 31 2011 1607 1616
34. A. Muñiz-Lozano, F. Rollini, F. Franchi, and D.J. Angiolillo Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice Ther Adv Cardiovasc Dis 7 2013 197 213
35. M. Valgimigli, M. Tebaldi, G. Campo FABOLUS PRO Investigators Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial J Am Coll Cardiol Intv 5 2012 268 277
36. J.L. Ferreiro, M. Ueno, and D.J. Angiolillo Cangrelor: a review on its mechanism of action and clinical development Expert Rev Cardiovasc Ther 7 2009 1195 1201
37. D. Capodanno, and D.J. Angiolillo Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery Circulation 128 2013 2785 2798
38. D.J. Angiolillo, M.S. Firstenberg, M.J. Price BRIDGE Investigators Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial JAMA 307 2012 265 274
39. S.R. Steinhubl, J.J. Oh, J.H. Oestreich, S. Ferraris, R. Charnigo, and W.S. Akers Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect Thromb Res 121 2008 527 534
40. N.L. Dovlatova, J.A. Jakubowski, A. Sugidachi, and S. Heptinstall The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function J Thromb Haemost 6 2008 1153 1159